Exploring ways to improve CDI outcomes.

Détails

ID Serval
serval:BIB_D9A97DB247AF
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Exploring ways to improve CDI outcomes.
Périodique
Medecine et maladies infectieuses
Auteur⸱e⸱s
Galpérine T., Guery B.
Collaborateur⸱rice⸱s
French Group of Fecal Microbiota Transplantation (GFTF)
ISSN
1769-6690 (Electronic)
ISSN-L
0399-077X
Statut éditorial
Publié
Date de publication
02/2018
Peer-reviewed
Oui
Volume
48
Numéro
1
Pages
10-17
Langue
anglais
Notes
Publication types: Journal Article ; Review
Publication Status: ppublish
Résumé
Clostridium difficile is an anaerobic spore-forming Gram-positive bacillus recognized as an evolving international health problem. Metronidazole and vancomycin were - until recently - the only drugs available to treat C. difficile infection (CDI). Better knowledge of the pathophysiology and the development of new drugs completely modified the management of initial episodes and recurrences of CDI. Fidaxomicin significantly reduced recurrences compared with vancomycin. New drugs are also currently evaluated (cadazolid, surotomycin, ridinilazole, rifaximin). Gut microbiota homeostasis was clearly shown to be a key determinant in recurrences as demonstrated by the development of gut microbiota transplantation and alternative microbiota substitution. Passive immunotherapy and vaccinal approaches are also currently being evaluated. In conclusion, CDI treatment has evolved with the development of new therapeutic pathways which now need to be implemented in international guidelines.

Mots-clé
Antibiotics, Antibiotiques, Clostridium difficile, Fecal microbiota transplantation, Transplantation fécale, Vaccin, Vaccine
Pubmed
Web of science
Création de la notice
25/01/2018 20:45
Dernière modification de la notice
30/01/2023 9:24
Données d'usage